Use of aldosterone antagonists to inhibit myocardial fibrosis

Details Use of aldosterone antagonists to inhibit myocardial fibrosis Use of aldosterone antagonists to inhibit myocardial fibrosis

A - Human Necessities

61

K

A61K 31/585 (2006.01)

Patent

CA 2177848

This invention discloses a method of using an aldosterone antagonist such as spironolactone and epoxymexrenone, at a dosage which does not disrupt a patient's normal electrolyte and water-retention balance, to inhibit myocardial fibrosis, including left ventricular hypertrophy (LVH).

L'invention concerne un procédé d'utilisation d'un antagoniste d'aldostérone tel que la spironolactone et l'époxymexrénone, en une posologie qui ne perturbe pas l'équilibre d'électrolyte et de rétention d'eau normal d'un patient, afin d'inhiber la fibrose myocardique, y compris l'hypertrophie ventriculaire gauche.

Affiliated with

Also associated with

Rating

Use of aldosterone antagonists to inhibit myocardial fibrosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of aldosterone antagonists to inhibit myocardial fibrosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of aldosterone antagonists to inhibit myocardial fibrosis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1394640